Do analysts recommend MRAI or XGN?

Exagen has a consensus target price of $9.11, indicating a potential upside of 94.68%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Exagen 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90

Which has stronger valuation & earnings, MRAI or XGN?

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 1.83 -$28.75M -$0.87 N/A Exagen $68.38M 1.65 -$19.95M -$0.89 N/A

Is MRAI or XGN more profitable?

Exagen has a net margin of -29.49% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Exagen -29.49% -94.37% -28.96%

Does the media favor MRAI or XGN?

In the previous week, Exagen had 2 more articles in the media than Marpai. MarketBeat recorded 3 mentions for Exagen and 1 mentions for Marpai. Exagen's average media sentiment score of 0.63 beat Marpai's score of 0.00 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exagen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BNR or MRAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer BNR or MRAI?

In the previous week, Burning Rock Biotech had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Burning Rock Biotech and 1 mentions for Marpai. Burning Rock Biotech's average media sentiment score of 1.68 beat Marpai's score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MRAI or SERA?

Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 168.29%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sera Prognostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has better earnings and valuation, MRAI or SERA?

Marpai has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 1.83 -$28.75M -$0.87 N/A Sera Prognostics $57K 1,408.35 -$31.93M -$0.65 N/A

Is MRAI or SERA more profitable?

Marpai has a net margin of -85.70% compared to Sera Prognostics' net margin of -56,385.97%. Marpai's return on equity of 0.00% beat Sera Prognostics' return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Sera Prognostics -56,385.97% -41.02% -30.95%

Do analysts rate PARK or MRAI?

Park Dental Partners currently has a consensus price target of $21.75, suggesting a potential upside of 15.88%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts clearly believe Park Dental Partners is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Park Dental Partners 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 2.75 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PARK or MRAI more profitable?

Park Dental Partners has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Park Dental Partners N/A N/A N/A Marpai -85.70% N/A -100.23%

Does the media prefer PARK or MRAI?

In the previous week, Park Dental Partners had 4 more articles in the media than Marpai. MarketBeat recorded 5 mentions for Park Dental Partners and 1 mentions for Marpai. Park Dental Partners' average media sentiment score of 0.63 beat Marpai's score of 0.00 indicating that Park Dental Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Park Dental Partners 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NAKA or MRAI?

KindlyMD presently has a consensus target price of $30.00, indicating a potential upside of 516.02%. Given KindlyMD's stronger consensus rating and higher possible upside, research analysts plainly believe KindlyMD is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KindlyMD 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, NAKA or MRAI?

Marpai has higher revenue and earnings than KindlyMD. Marpai is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KindlyMD $1.82M 46.56 -$52.23M -$43.20 N/A Marpai $34.87M 1.83 -$28.75M -$0.87 N/A

Is NAKA or MRAI more profitable?

Marpai has a net margin of -85.70% compared to KindlyMD's net margin of -7,397.12%. Marpai's return on equity of 0.00% beat KindlyMD's return on equity. Company Net Margins Return on Equity Return on Assets KindlyMD -7,397.12% -81.32% -54.17% Marpai -85.70% N/A -100.23%

Does the media refer more to NAKA or MRAI?

In the previous week, KindlyMD had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for KindlyMD and 1 mentions for Marpai. KindlyMD's average media sentiment score of 1.31 beat Marpai's score of 0.00 indicating that KindlyMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KindlyMD 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Marpai (MRAI) Competitors

$2.37 +0.18 (+8.22%)

As of 07/24/2026 03:56 PM Eastern

Compare

MRAI vs. XGN, BNR, SERA, PARK, and NAKA

Should you buy Marpai stock or one of its competitors? MarketBeat compares Marpai with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marpai include Exagen (XGN), Burning Rock Biotech (BNR), Sera Prognostics (SERA), Park Dental Partners (PARK), and KindlyMD (NAKA). These companies are all part of the "healthcare" industry.

How does Marpai compare to Exagen?

Marpai (NASDAQ:MRAI) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Marpai has a beta of 4.92, meaning that its stock price is 392% more volatile than the broader market. Comparatively, Exagen has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market.

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.83	-$28.75M	-$0.87	N/A
Exagen	$68.38M	1.65	-$19.95M	-$0.89	N/A

49.8% of Marpai shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 10.4% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Exagen had 2 more articles in the media than Marpai. MarketBeat recorded 3 mentions for Exagen and 1 mentions for Marpai. Exagen's average media sentiment score of 0.63 beat Marpai's score of 0.00 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exagen has a consensus target price of $9.11, indicating a potential upside of 94.68%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Exagen has a net margin of -29.49% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Exagen	-29.49%	-94.37%	-28.96%

Summary

Exagen beats Marpai on 11 of the 17 factors compared between the two stocks.

How does Marpai compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and Marpai (NASDAQ:MRAI) are both small-cap business services companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Burning Rock Biotech has a net margin of -11.57% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Marpai	-85.70%	N/A	-100.23%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Burning Rock Biotech has higher revenue and earnings than Marpai. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$514.43M	0.18	-$7.92M	-$0.82	N/A
Marpai	$34.87M	1.83	-$28.75M	-$0.87	N/A

In the previous week, Burning Rock Biotech had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Burning Rock Biotech and 1 mentions for Marpai. Burning Rock Biotech's average media sentiment score of 1.68 beat Marpai's score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Burning Rock Biotech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Marpai has a beta of 4.92, suggesting that its stock price is 392% more volatile than the broader market.

Summary

Burning Rock Biotech beats Marpai on 8 of the 14 factors compared between the two stocks.

How does Marpai compare to Sera Prognostics?

Marpai (NASDAQ:MRAI) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Marpai has a net margin of -85.70% compared to Sera Prognostics' net margin of -56,385.97%. Marpai's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 168.29%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

49.8% of Marpai shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Marpai has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.83	-$28.75M	-$0.87	N/A
Sera Prognostics	$57K	1,408.35	-$31.93M	-$0.65	N/A

In the previous week, Marpai and Marpai both had 1 articles in the media. Sera Prognostics' average media sentiment score of 1.89 beat Marpai's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
Sera Prognostics	Very Positive

Marpai has a beta of 4.92, indicating that its stock price is 392% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Summary

Sera Prognostics beats Marpai on 9 of the 16 factors compared between the two stocks.

How does Marpai compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Park Dental Partners has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

Park Dental Partners currently has a consensus price target of $21.75, suggesting a potential upside of 15.88%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts clearly believe Park Dental Partners is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Park Dental Partners had 4 more articles in the media than Marpai. MarketBeat recorded 5 mentions for Park Dental Partners and 1 mentions for Marpai. Park Dental Partners' average media sentiment score of 0.63 beat Marpai's score of 0.00 indicating that Park Dental Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Park Dental Partners	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Park Dental Partners has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.35	-$360K	$0.74	25.36
Marpai	$34.87M	1.83	-$28.75M	-$0.87	N/A

49.8% of Marpai shares are held by institutional investors. 10.6% of Park Dental Partners shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Park Dental Partners beats Marpai on 11 of the 14 factors compared between the two stocks.

How does Marpai compare to KindlyMD?

KindlyMD (NASDAQ:NAKA) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, KindlyMD had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for KindlyMD and 1 mentions for Marpai. KindlyMD's average media sentiment score of 1.31 beat Marpai's score of 0.00 indicating that KindlyMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KindlyMD	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

KindlyMD presently has a consensus target price of $30.00, indicating a potential upside of 516.02%. Given KindlyMD's stronger consensus rating and higher possible upside, research analysts plainly believe KindlyMD is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

49.8% of Marpai shares are held by institutional investors. 24.5% of KindlyMD shares are held by insiders. Comparatively, 46.1% of Marpai shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

KindlyMD has a beta of 16.05, indicating that its share price is 1,505% more volatile than the broader market. Comparatively, Marpai has a beta of 4.92, indicating that its share price is 392% more volatile than the broader market.

Marpai has a net margin of -85.70% compared to KindlyMD's net margin of -7,397.12%. Marpai's return on equity of 0.00% beat KindlyMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KindlyMD	-7,397.12%	-81.32%	-54.17%
Marpai	-85.70%	N/A	-100.23%

Marpai has higher revenue and earnings than KindlyMD. Marpai is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KindlyMD	$1.82M	46.56	-$52.23M	-$43.20	N/A
Marpai	$34.87M	1.83	-$28.75M	-$0.87	N/A

Summary

KindlyMD beats Marpai on 9 of the 16 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	health & allied services, not elsewhere classified Industry	Business Sector	NASDAQ Exchange
Market Cap	$63.68M	$98.29M	$6.82B	$12.26B
Dividend Yield	N/A	N/A	3.09%	9.79%
P/E Ratio	-0.90	0.74	28.15	23.64
Price / Sales	1.83	0.96	313.05	89.27
Price / Cash	N/A	4.19	22.68	59.64
Price / Book	-1.38	0.15	5.46	6.07
Net Income	-$28.75M	$25.15M	$205.01M	$331.99M
7 Day Performance	50.96%	17.06%	-1.95%	-0.63%
1 Month Performance	264.62%	86.57%	-2.71%	-2.00%
1 Year Performance	80.92%	62.59%	4.47%	13.62%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$2.37 +8.2%	N/A	+76.9%	$63.68M	$34.87M	N/A	150	High Trading Volume
XGN Exagen	2.7749 of 5 stars	$4.94 +1.6%	$9.11 +84.4%	-35.2%	$117.42M	$66.57M	N/A	220	News Coverage
BNR Burning Rock Biotech	1.3835 of 5 stars	$9.14 -3.3%	N/A	+7.6%	$99.40M	$77.16M	N/A	1,390	News Coverage
SERA Sera Prognostics	3.5975 of 5 stars	$2.08 -8.4%	$5.50 +164.4%	-36.9%	$88.89M	$80K	N/A	120	Positive News
PARK Park Dental Partners	3.7492 of 5 stars	$19.44 +0.8%	$21.75 +11.9%	N/A	$87.05M	$244.49M	26.27	1,212	News Coverage Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors

MRAI vs. XGN, BNR, SERA, PARK, and NAKA

How does Marpai compare to Exagen?

Summary

How does Marpai compare to Burning Rock Biotech?

Summary

How does Marpai compare to Sera Prognostics?

Summary

How does Marpai compare to Park Dental Partners?

Summary

How does Marpai compare to KindlyMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marpai (MRAI) Competitors

MRAI vs. XGN, BNR, SERA, PARK, and NAKA

How does Marpai compare to Exagen?

Which has more volatility & risk, MRAI or XGN?

Which has stronger valuation & earnings, MRAI or XGN?

Do insiders & institutionals believe in MRAI or XGN?

Does the media favor MRAI or XGN?

Do analysts recommend MRAI or XGN?

Is MRAI or XGN more profitable?

Summary

How does Marpai compare to Burning Rock Biotech?

Is BNR or MRAI more profitable?

Do analysts recommend BNR or MRAI?

Do institutionals and insiders have more ownership in BNR or MRAI?

Which has preferable valuation and earnings, BNR or MRAI?

Does the media prefer BNR or MRAI?

Which has more risk and volatility, BNR or MRAI?

Summary

How does Marpai compare to Sera Prognostics?

Is MRAI or SERA more profitable?

Do analysts rate MRAI or SERA?

Do institutionals & insiders have more ownership in MRAI or SERA?

Which has better earnings and valuation, MRAI or SERA?

Does the media favor MRAI or SERA?

Which has more volatility & risk, MRAI or SERA?

Summary

How does Marpai compare to Park Dental Partners?

Is PARK or MRAI more profitable?

Do analysts rate PARK or MRAI?

Does the media prefer PARK or MRAI?

Which has stronger valuation & earnings, PARK or MRAI?

Do institutionals and insiders hold more shares of PARK or MRAI?

Summary

How does Marpai compare to KindlyMD?

Does the media refer more to NAKA or MRAI?

Do analysts recommend NAKA or MRAI?

Do insiders and institutionals believe in NAKA or MRAI?

Which has more risk and volatility, NAKA or MRAI?

Is NAKA or MRAI more profitable?

Which has stronger valuation & earnings, NAKA or MRAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools